학술논문
Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS.
Document Type
article
Author
Nirupama Putcha; Gabriel G Paul; Antoine Azar; Robert A Wise; Wanda K O'Neal; Mark T Dransfield; Prescott G Woodruff; Jeffrey L Curtis; Alejandro P Comellas; M Bradley Drummond; Allison A Lambert; Laura M Paulin; Ashraf Fawzy; Richard E Kanner; Robert Paine; MeiLan K Han; Fernando J Martinez; Russell P Bowler; R Graham Barr; Nadia N Hansel; SPIROMICS investigators
Source
PLoS ONE, Vol 13, Iss 4, p e0194924 (2018)
Subject
Language
English
ISSN
1932-6203
Abstract
BACKGROUND:Decreased but measurable serum IgA levels (≤70 mg/dL) have been associated with risk for infections in some populations, but are unstudied in COPD. This study tested the hypothesis that subnormal serum IgA levels would be associated with exacerbation risk in COPD. METHODS:Data were analyzed from 1,049 COPD participants from the observational cohort study SPIROMICS (535 (51%) women; mean age 66.1 (SD 7.8), 338 (32%) current smokers) who had baseline serum IgA measured using the Myriad RBM biomarker discovery platform. Exacerbation data was collected prospectively (mean 944.3 (SD 281.3) days), and adjusted linear, logistic and zero-inflated negative binomial regressions were performed. RESULTS:Mean IgA was 269.1 mg/dL (SD 150.9). One individual had deficient levels of serum IgA (